Novo Holdings, an international life science investor, announced a £50 million investment in Oxford Nanopore Technologies, a UK Listed company behind a new generation of molecular sensing technology based on nanopores.
Oxford Nanopore has developed a new generation of molecular analysis technology used for DNA/RNA sequencing. The technology is designed to offer rich data including epigenetics, rapid insights through real-time workflows and portable formats, in a way that is accessible and affordable.
The technology is used increasingly in clinical and applied industrial settings including biopharma. Access to fast, information-rich molecular information has the potential to play a critical role across the biopharma industry, from drug discovery to commercialization.
In particular, direct RNA sequencing can enable biologics manufacturing and quality control processes for an emerging class of mRNA-based products, potentially replacing multiple technologies with a single, streamlined platform. Furthermore, the generation of epigenetic data (variation in DNA information that can influence many diseases such as cancer) in large-scale studies can promote discoveries.
Dr. Daniel Mahony, Senior Partner, Growth Investments, Novo Holdings, said, “Oxford Nanopore has made impressive ongoing progress to advance its technology platform and gain commercial traction. This investment underscores our belief in Oxford Nanopore’s platform and its expanding opportunity in biopharmaceuticals, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new drug therapies.”
Dr. Gordon Sanghera, Chief Executive Officer, Oxford Nanopore added, “Novo Holdings is one of the world’s top life sciences investors, and we are delighted to welcome them as a long-term shareholder. The Novo Holdings team brings deep knowledge of the biopharmaceutical market, including biomanufacturing, a key growth area for Oxford Nanopore. We look forward to their support given our commitment to biopharma as one of our strategic growth vectors.”
https://www.contractpharma.com/contents/view_breaking-news/2024-08-01/novo-holdings-invests-50m-in-oxford-nanopore/9769

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
